Search Result

Results for "

oncogenic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (2) Apoptosis (13) Aurora Kinase (1) Autophagy (2) Bcr-Abl (1) c-Myc (2) CDK (1) DNA/RNA Synthesis (2) EGFR (4) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Farnesyl Transferase (2) Hedgehog (2) Histone Methyltransferase (2) HSP (2) HuR (1) Lactate Dehydrogenase (1) MDM-2/p53 (1) MEK (1) MicroRNA (1) Microtubule/Tubulin (1) PAK (3) PDGFR (2) PDHK (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PKC (1) PROTACs (4) Raf (1) Ras (13) Reactive Oxygen Species (1) RET (2) SHP2 (1) Smo (1) TAM Receptor (1) YAP (1)
By Research Areas:	Cancer (58) Infection (4) Inflammation/Immunology (1)

By Targets:

Akt (1)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (2)

Apoptosis (13)

Aurora Kinase (1)

Autophagy (2)

Bcr-Abl (1)

c-Myc (2)

CDK (1)

DNA/RNA Synthesis (2)

EGFR (4)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

Farnesyl Transferase (2)

Hedgehog (2)

Histone Methyltransferase (2)

HSP (2)

HuR (1)

Lactate Dehydrogenase (1)

MDM-2/p53 (1)

MEK (1)

MicroRNA (1)

Microtubule/Tubulin (1)

PAK (3)

PDGFR (2)

PDHK (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PKC (1)

PROTACs (4)

Raf (1)

Ras (13)

Reactive Oxygen Species (1)

RET (2)

SHP2 (1)

Smo (1)

TAM Receptor (1)

YAP (1)

By Research Areas:

Cancer (58)

Infection (4)

Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W048303

L-Azatyrosine	Antibiotic	Infection Cancer
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes .

HY-125636

Mycro1	Others	Cancer
Mycro1 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC₅₀ value of 30 μM for the inhibition of Myc/Max DNA binding activity. Mycro1 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation .

HY-126979

Mycro2	Others	Cancer
Mycro2 is an inhibitor of c-Myc/Max dimer and DNA binding, with an IC₅₀ value of 23 μM for the inhibition of Myc/Max DNA binding activity. Mycro2 can inhibit c-myc-dependent cell proliferation, gene transcription and oncogenic transformation .

HY-143713

Aurora A inhibitor 1	Aurora Kinase	Cancer
Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49) .

HY-151287

KRAS inhibitor-20

Ras Cancer

KRAS inhibitor-20 is a small molecular inhibitor of KRas ^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas ^G12C with the IC50 value <10 nM .

KRAS inhibitor-20	Ras	Cancer
KRAS inhibitor-20 is a small molecular inhibitor of KRas ^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas ^G12C with the IC50 value <10 nM .

HY-144256

CHD1Li 6.11	Others	Cancer
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC₅₀=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties .

HY-120373

MB710	MDM-2/p53	Cancer
MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a K_d of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines .

HY-150926

G12Si-1	Ras	Cancer
G12Si-1 is a selective K-Ras(G12S) covalent inhibitor, which can inhibit oncogenic signaling of K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S) at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange .

HY-149241

SHP2-IN-13	SHP2	Cancer
SHP2-IN-13 is a highly selective and orally active SHP2 “tunnel site” allosteric inhibitor with an IC50 of 83.0 nM. SHP2-IN-13 has the potential for cancers bearing RTK oncogenic drivers and SHP2-related diseases research.

HY-12408

6H05

Ras Cancer

6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
HY-157228

ACBI3

Others Cancer

ACBI3 (compound 7) is a pan-KRAS degrader. ACBI3 achieves in vivo degradation of oncogenic KRAS .

6H05	Ras	Cancer
6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).

ACBI3	Others	Cancer
ACBI3 (compound 7) is a pan-KRAS degrader. ACBI3 achieves in vivo degradation of oncogenic KRAS .

HY-117548

UNC1062 1 Publications Verification	TAM Receptor	Cancer
UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. UNC1062 potently inhibits MERTK kinase activity (MERTK IC₅₀=1.1 nM, Morrison K_i=0.33 nM) and exhibits specificity within the TAM family (TYRO3 IC₅₀=60 nM, AXL IC₅₀=85 nM) .

HY-12408A

6H05 TFA

Ras Cancer

6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).

6H05 TFA	Ras	Cancer
6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).

HY-147361

LDCA	Apoptosis Lactate Dehydrogenase	Cancer
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .

HY-14754

Salirasib Maximum Cited Publications 7 Publications Verification S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS	Ras Autophagy	Cancer
Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

HY-162350

TDI-11055	Endogenous Metabolite	Cancer
TDI-11055 is an inhibitor of the epigenetic reader protein 11-19 leukemia (ENL) YEATS, which drives the oncogenic transcriptional program of acute myeloid leukemia (AML), the hematopoietic malignancy AML .

HY-108508

SMANT hydrochloride	Smo Hedgehog	Cancer
SMANT hydrochloride is a Smoothened (Smo) signaling inhibitor. SMANT hydrochloride is antagonist of Smo accumulation within the primary cilium (PC). SMANT hydrochloride has an equivalent activity in inhibiting SmoM2 (oncogenic form of Smo) and wild-type Smo .

HY-15872

FTI-277	Farnesyl Transferase Apoptosis Ras	Infection Cancer
FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and *K-Ras oncogenic* signaling. FTI-277 can inhibit hepatitis delta virus (HDV)** infection.

HY-15872A

FTI-277 hydrochloride 3 Publications Verification	Farnesyl Transferase Apoptosis Ras	Infection Cancer
FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and *K-Ras oncogenic* signaling. FTI-277 hydrochloride can inhibit hepatitis delta virus (HDV)** infection.

HY-N11794

7-Ketologanin	Others	Others
7-Ketologanin is an iridoid glucoside. 7-Ketologanin can be isolated from the Stems of Viburnum erosum. 7-Ketologanin involves in biosynthetic pathway of oleuropein. Oleuropein, is a bioactive phenolic compound, modulates several oncogenic signalling pathways .

HY-106381

Aurothiomalate sodium	PKC	Inflammation/Immunology Cancer
Aurothiomalate sodium is a potent and selective oncogenic PKC_ι signaling inhibitor. Aurothiomalate sodium inhibits tumor cell proliferation and not cell apoptosis. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium, an anti-rheumatoid agent, exhibits potent anti-tumor activity .

HY-108436

Deltazinone 1	Phosphodiesterase (PDE)	Cancer
Deltazinone 1, a pyrazolopyridazinone, is a highly selective PDEδ inhibitor with a K_D of 8 nM. Deltazinone 1 inhibits the PDEδ-Ras interaction. Deltazinone 1 shows a dose-dependent inhibitory response on proliferation in oncogenic KRas-dependent cell lines .

HY-153534

microRNA-21-IN-3	MicroRNA	Cancer
microRNA-21-IN-3 (compound 45) can specifically bind to the precursor of oncogenic and pro-inflammatory microRNA-21 with medium nanomolar affinity, reduce cancer cell proliferation and miR-21 levels, and can be used in antitumor research .

HY-162126

Tubulin polymerization-IN-58	Microtubule/Tubulin YAP	Cancer
Tubulin polymerization-IN-58 (Compound K18) is a tubulin polymerization inhibitor with an IC₅₀ of 0.446 μM. Tubulin polymerization-IN-58 also induces the degradation of oncogenic protein YAP via the UPS pathway, thus can be used for cancer research .

HY-134582

dCBP-1 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .

HY-153386

CPD-1224	Anaplastic lymphoma kinase (ALK)	Cancer
CPD-1224 is an orally active derivative of ALK inhibitors to cereblon ligands. CPD-1224 targets to EML4-ALK oncogenic fusions, and degrades ALK and mutant L1196M/G1202R .

HY-135815

Mobocertinib 5+ Cited Publications TAK-788; AP32788	EGFR	Cancer
Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research .

HY-135815B

Mobocertinib mesylate TAK-788 mesylate; AP32788 mesylate	EGFR	Cancer
Mobocertinib (TAK-788) mesylate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research .

HY-139402

MRTX849 acid	Ras	Cancer
MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC₅₀s between 0.25 and 0.76 μM) .

HY-135815A

Mobocertinib succinate 5+ Cited Publications TAK-788 succinate; AP32788 succinate	EGFR	Cancer
Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research .

HY-139065

AMPC	Others	Cancer
AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research .

HY-120909

YK5	HSP Apoptosis	Cancer
YK5 is a potent and selective Hsp70 inhibitor. YK5 selectively and tightly binds to the cytosolic Hsp70s in cancer cells. YK5 has biological activity partly by interfering with the formation of active oncogenic Hsp70/Hsp90/client protein complexes .

HY-122866

ZT-12-037-01	Ras	Cancer
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC₅₀ of 24 nM .

HY-144096

EZH2-IN-11	Histone Methyltransferase	Cancer
EZH2-IN-11 is a potent inhibitor of E2HZ. The oncogenic activities of EZH2 have been shown by a number of studies in various different cancer types. EZH2-IN-11 has the potential for the research of cancer diseases (extracted from patent WO2019204490A1, compound 17) .

HY-124844

Azaphilone-9 AZA-9	HuR	Cancer
Azaphilone-9 (AZA-9) is an inhibitor of HuR-ARE RNA interaction (IC₅₀=1.2 μM) by binding RNA-binding protein Hu antigen R (HuR). The HuR-RNA interactions stabilize many oncogenic mRNAs in tumors. Thus Azaphilone-9 potentially inhibit cancer cell growth and progression .

HY-13007

PF-3758309 Maximum Cited Publications 7 Publications Verification PF-03758309	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-13007B

PF-3758309 dihydrochloride PF-03758309 dihydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) dihydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 dihydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-13007A

PF-3758309 hydrochloride PF-03758309 hydrochloride	PAK Apoptosis	Cancer
PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .

HY-100627

APS-2-79	MEK	Cancer
APS-2-79 is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-136789

Tuxobertinib BDTX-189	EGFR	Cancer
Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity .

HY-100627A

APS-2-79 hydrochloride
APS-2-79 hydrochloride is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-147918

Anticancer agent 73	DNA/RNA Synthesis	Cancer
Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .

HY-125834

GMB-475	PROTACs Bcr-Abl Apoptosis	Cancer
GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent agent resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein .

HY-156084

LL-K9-3	CDK PROTACs Apoptosis c-Myc	Cancer
LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs .

HY-14507

YK-4-279 5 Publications Verification	DNA/RNA Synthesis Apoptosis	Cancer
YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein). YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer .

HY-13425

Deguelin 5 Publications Verification (-)-Deguelin; (-)-cis-Deguelin	Akt Autophagy Apoptosis	Cancer
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-162250

MS8847	PROTACs Histone Methyltransferase	Cancer
MS8847 is a highly potent EZH2 PROTAC degrader that recruits the E3 ligase von Hippel-Lindau (VHL). MS8847 potently degrades EZH2 in a ubiquitin-proteasome system-dependent manner. MS8847 effectively inhibits the growth of acute myeloid leukemia (AML) and triple-negative breast cancer (TNBC) cells .

HY-19625

MCB-613	Reactive Oxygen Species	Cancer
MCB-613 is a potent Steroid receptor coactivator SRC small molecule ‘stimulator’ (SMS), super-stimulates SRCs’ transcriptional activity. MCB-613 increases SRCs’ interactions with other coactivators and markedly induces ER stress coupled to the generation of reactive oxygen species (ROS). MCB-613 is a SMS that target oncogenes can be exploited as anti-cancer agents by over-stimulating the SRC oncogenic program .

HY-139590

Zeteletinib BOS-172738; DS-5010	RET PDGFR	Cancer
Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RET ^V804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity .

HY-143400

HSP70-IN-3	HSP Hedgehog	Cancer
HSP70-IN-3 is a potent HSP70 inhibitor (IC₅₀s of 1.1 and 1.9 μM in ASZ001 and C3H10T1/2, respectively). HSP70-IN-3 has anti-Hh (Hedgehog signaling) activity and anti-proliferative activity and reduces expression of the oncogenic transcription factor GLI1 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks